title: Teniposide and cytarabine combination chemotherapy in the treatment of relapsed adolescent and adult acute lymphoblastic leukemia.
abstract: Nineteen adolescents and adults with relapsed acute lymphoblastic leukemia (ALL) were treated with teniposide (VM-26) plus cytarabine (ara-C). Eight patients (42%) achieved complete remission. Infection and bleeding secondary to myelosuppression were the most serious complications seen. Responders received periodic reinductions with VM-26 and ara-C, but all relapsed within 16 weeks from remission. Our data demonstrate the effectiveness of combination chemotherapy with VM-26 plus ara-C in adolescent and adult ALL in relapse and suggest testing of this combination in first-line protocols. For remission maintenance, the association of other drug combinations is necessary.
authors.forename: G F
authors.initials: GF
authors.lastname: Sanz
authors.forename: M A
authors.initials: MA
authors.lastname: Sanz
authors.forename: F J
authors.initials: FJ
authors.lastname: Rafecas
authors.forename: J A
authors.initials: JA
authors.lastname: Martínez
authors.forename: G
authors.initials: G
authors.lastname: Martín-Aragonés
authors.forename: M L
authors.initials: ML
authors.lastname: Marty
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009423:Nervous System Neoplasms / Q000517:prevention & control; D013713:Teniposide / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D013713:Teniposide